PMID- 23723293
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20211021
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 10
DP  - 2013 Oct
TI  - A comparison of hormonal profiles between breast cancer and benign breast 
      disease: a case-control study.
PG  - 2527-2533
LID - S0923-7534(19)37073-5 [pii]
LID - 10.1093/annonc/mdt207 [doi]
AB  - BACKGROUND: Benign breast disease (BBD), particularly proliferative BBD, is an 
      established breast cancer risk factor. However, there has been no systematic 
      attempt to compare the hormonal profiles of the two conditions. In a case-control 
      investigation in Athens, Greece, we compared levels of estrogens, testosterone 
      and insulin-like growth factor-1 (IGF-1), as well as their principal binding 
      proteins, between breast cancer patients, women with BBD by histological type 
      (proliferative and nonproliferative) and women with no breast pathology. PATIENTS 
      AND METHODS: We studied 466 women with incident breast cancer, 704 women with BBD 
      and 244 healthy women. We used multiple regression to compare log-transformed 
      serum hormone levels of breast cancer patients with those of healthy women and 
      women with BBD by histological type (proliferative and nonproliferative BBD). 
      RESULTS: The hormonal profile of breast cancer in our study was in line with the 
      generally accepted hormonal profile of this disease, as reported from large 
      cohort studies. Compared with healthy women, breast cancer patients tended to 
      have higher levels of steroid hormones. The evidence was strong for estrone 
      (difference 21.5%, P < 0.001), weaker for testosterone (difference 15.8%, P = 
      0.07) and weaker still for estradiol (difference 12.0%, P = 0.18). Also compared 
      with healthy women, breast cancer patients had barely higher levels of IGF-1 
      (difference 2.0%, P = 0.51), but had significantly lower levels of IGF binding 
      protein 3 (IGFBP-3) (difference -6.7%, P = 0.001). Compared with women with BBD, 
      breast cancer patients had nonstatistically significantly lower levels of steroid 
      hormones, but they had higher levels of IGF-1 [difference 5.5%, 95% confidence 
      interval (CI) 0.7% to 10.6%] and lower levels of IGFBP-3 (difference -3.7%, 95% 
      CI -6.7% to -0.7%). Differences were more pronounced when breast cancer patients 
      were contrasted to women with proliferative BBD. CONCLUSIONS: Our findings 
      suggest that high levels of IGF-1 may be an important factor toward the evolution 
      of BBD to breast cancer.
FAU - Lagiou, P
AU  - Lagiou P
AD  - Department of Hygiene, Epidemiology and Medical Statistics, University of Athens 
      Medical School, Athens, Greece; Department of Epidemiology, Harvard School of 
      Public Health, Boston, USA; Bureau of Epidemiologic Research, Academy of Athens, 
      Athens. Electronic address: pdlagiou@med.uoa.gr.
FAU - Samoli, E
AU  - Samoli E
AD  - Department of Hygiene, Epidemiology and Medical Statistics, University of Athens 
      Medical School, Athens, Greece.
FAU - Lagiou, A
AU  - Lagiou A
AD  - Faculty of Health Professions, Athens Technological Educational Institute, 
      Athens.
FAU - Zourna, P
AU  - Zourna P
AD  - Department of Hygiene, Epidemiology and Medical Statistics, University of Athens 
      Medical School, Athens, Greece.
FAU - Barbouni, A
AU  - Barbouni A
AD  - Bureau of Epidemiologic Research, Academy of Athens, Athens; Department of Public 
      and Administrative Health, National School of Public Health, Athens.
FAU - Georgila, C
AU  - Georgila C
AD  - Department of Hygiene, Epidemiology and Medical Statistics, University of Athens 
      Medical School, Athens, Greece.
FAU - Tsikkinis, A
AU  - Tsikkinis A
AD  - First Department of Surgery, Elena Venizelou Hospital, Athens.
FAU - Vassilarou, D
AU  - Vassilarou D
AD  - 'Prolipsis' Diagnostic Center, Athens.
FAU - Minaki, P
AU  - Minaki P
AD  - Department of Hygiene, Epidemiology and Medical Statistics, University of Athens 
      Medical School, Athens, Greece.
FAU - Sfikas, C
AU  - Sfikas C
AD  - Department of Pathology, Elena Venizelou Hospital, Athens.
FAU - Spanos, E
AU  - Spanos E
AD  - 'Biomedicine' Diagnostic Center, Athens, Greece.
FAU - Trichopoulos, D
AU  - Trichopoulos D
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, USA; Bureau 
      of Epidemiologic Research, Academy of Athens, Athens.
LA  - eng
GR  - CA89823/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130530
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Estrogens)
RN  - 0 (IGFBP3 protein, human)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 3XMK78S47O (Testosterone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Breast Diseases/blood/metabolism
MH  - Breast Neoplasms/*blood/metabolism
MH  - Case-Control Studies
MH  - Estrogens/*blood
MH  - Female
MH  - Greece
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Middle Aged
MH  - Risk Factors
MH  - Testosterone/*blood
PMC - PMC3784331
OTO - NOTNLM
OT  - IGF-1
OT  - benign breast disease
OT  - breast cancer
OT  - epidemiology
OT  - proliferative
OT  - steroid hormones
EDAT- 2013/06/01 06:00
MHDA- 2014/05/16 06:00
PMCR- 2014/10/01
CRDT- 2013/06/01 06:00
PHST- 2013/06/01 06:00 [entrez]
PHST- 2013/06/01 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - S0923-7534(19)37073-5 [pii]
AID - mdt207 [pii]
AID - 10.1093/annonc/mdt207 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Oct;24(10):2527-2533. doi: 10.1093/annonc/mdt207. Epub 2013 May 
      30.